Long-Term Efficacy and Safety of Infliximab plus Methotrexate for The Treatment of Polyarticular Course Juvenile Rheumatoid Arthritis: Findings from an Open-Label Treatment Extension (vol 69, pg 585, 2010)

被引：0
|
作者：
Ruperto, Nicolino
Lovell, Daniel J.
Cuttica, Ruben
机构：
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2012年 / 71卷 / 06期
关键词：
D O I：
10.1136/ard.2008.100354
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1106 / 1106
页数：1
相关论文
共 50 条
  • [21] Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study
    Baker, Milton
    Chalabi, Youb
    Genovese, Mark
    Taylor, Peter
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    Keystone, Edward
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1505 - 1505
  • [22] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    [J]. Arthritis Research & Therapy, 21
  • [23] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Wood, Susan P.
    Terry, Ketti K.
    Nakamura, Hiroyuki
    Ohno, Yukako
    Gruben, David
    Benda, Birgitta
    Wang, Lisy
    Riese, Richard
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993
  • [24] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
    Wollenhaupt, Jurgen
    Silverfield, Joel C.
    Lee, Eun Bong
    Wood, Susan P.
    Soma, Koshika
    Wang, Lisy
    Nakamura, Hiroyuki
    Komuro, Yoshihiro
    Nduaka, Chudi I.
    Gruben, David
    Benda, Birgitta
    Zwillich, Samuel H.
    Riese, Richard
    Bradley, John D.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S548 - S549
  • [25] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION UP TO 6 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K. K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 259 - 259
  • [26] THE EFFICACY AND SAFETY OF AURANOFIN IN THE TREATMENT OF JUVENILE RHEUMATOID-ARTHRITIS - A LONG-TERM OPEN STUDY
    MARCOLONGO, R
    MATHIEU, A
    PALA, R
    GIORDANO, N
    FIORAVANTI, A
    PANZARASA, R
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (08): : 979 - 983
  • [27] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8
    Pope, Janet
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Haraoui, Boulos
    [J]. JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 879 - 879
  • [28] Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies
    Burmester, Gerd
    Strand, Vibeke
    Kivitz, Alan
    Hu, Chih-Chi
    Wang, Sheldon
    van Hoogstraten, Hubert
    Tao, Ray
    Fleischmann, Roy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3521 - 3525
  • [29] Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Wollenhaupt, Juergen
    Lee, Eun-Bong
    Curtis, Jeffrey R.
    Silverfield, Joel
    Terry, Ketti
    Soma, Koshika
    Mojcik, Chris
    DeMasi, Ryan
    Strengholt, Sander
    Kwok, Kenneth
    Lazariciu, Irina
    Wang, Lisy
    Cohen, Stanley
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [30] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Terry, Ketti
    Kwok, Kenneth
    Strengholt, Sander
    DeMasi, Ryan
    Wang, Lisy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345